Novo Nordisk has received US regulatory approval for Wegovy® HD (semaglutide 7.2 mg), representing a significant advancement in pharmacological obesity management. This higher-dose formulation of the GLP-1 receptor agonist semaglutide is designed to address unmet needs in patients who do not achieve adequate weight loss with existing therapies. The approval is supported by robust data from the phase 3 STEP UP clinical trial program, which evaluated the efficacy and safety of once-weekly semaglutide 7.2 mg in adults with obesity.
The 2026 consensus statement from the American Association of Clinical Endocrinology reflects a continued evolution in endocrine care, emphasizing a comprehensive, patient-centered, and multidisciplinary framework for managing cardiometabolic diseases. Building on prior AACE guidance and algorithms, the statement integrates the latest evidence with practical clinical strategies to address conditions such as obesity, diabetes, dyslipidemia, and related metabolic disorders.
The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia represents a major update in lipid management, integrating contemporary evidence to optimize prevention of atherosclerotic cardiovascular disease (ASCVD). The guideline provides a comprehensive, life-course approach to the evaluation, treatment, and monitoring of dyslipidemias, encompassing both primary and secondary prevention strategies.
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by joint inflammation, structural damage, and associated skin manifestations of psoriasis. Despite the availability of several biologic and targeted therapies, many patients continue to experience persistent disease activity or treatment intolerance, highlighting the need for additional therapeutic options. Deucravacitinib (Sotyktu), an oral selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb, has now received approval from the U.S. Food and Drug Administration for the treatment of adults with active psoriatic arthritis. This approval represents the first TYK2 inhibitor authorized for this indication and introduces a novel mechanism targeting intracellular cytokine signaling pathways involved in immune-mediated inflammation.
Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder characterized by progressive muscle degeneration caused by mutations in the dystrophin gene. Z-rostudirsen (DYNE-251) is an investigational exon-51–skipping therapy designed to restore the production of functional dystrophin by enabling targeted delivery of a phosphorodiamidate morpholino oligomer to muscle tissue. Dyne Therapeutics recently reported new cardiopulmonary and long-term clinical results from the Phase 1/2 DELIVER trial evaluating this therapy in individuals with DMD amenable to exon 51 skipping.
